Novo Nordisk and Eli Lilly Launch Weight-Loss Drugs Targeting $150 Billion Market
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1h ago
0mins
Source: Newsfilter
- Massive Market Potential: The global obesity market is projected to reach $150 billion by 2030, with Novo Nordisk and Eli Lilly launching oral weight-loss medications to meet rising consumer demand, significantly enhancing their market share and revenue potential.
- Increased Accessibility: Novo's Wegovy oral medication is expected to launch in January 2026 at a price of $149 per month, aimed at reducing the economic burden on consumers through cash-pay channels, thereby expanding the drug's market coverage.
- Shift to Consumer Focus: The promotion of these medications will no longer rely on traditional healthcare systems, as Novo and Lilly are partnering with telehealth platforms to sell directly to consumers, which is expected to transform the obesity drug market landscape.
- Celebrity Endorsement Impact: Endorsements from celebrities like Serena Williams have boosted awareness of GLP-1 medications, increasing consumer acceptance of weight-loss drugs and further accelerating rapid market growth.
LLY
$1077.75+Infinity%1D
Analyst Views on LLY
Wall Street analysts forecast LLY stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for LLY is 1078 USD with a low forecast of 800.00 USD and a high forecast of 1300 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
20 Analyst Rating
18 Buy
2 Hold
0 Sell
Strong Buy
Current: 1076.980
Low
800.00
Averages
1078
High
1300
Current: 1076.980
Low
800.00
Averages
1078
High
1300
About LLY
Eli Lilly and Company is a medicine company, which discovers, develops, manufactures, markets, and sells pharmaceutical products worldwide. Its cardiometabolic health products include Basaglar; Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, and others; Humulin, Humulin 70/30, and others; Jardiance; Mounjaro; Trulicity; Zepbound; VERVE-102; VERVE-201, and VERVE-301. Its oncology products include Cyramza, Erbitux, Tyvyt, and Verzenio. Its immunology products include Ebglyss, Olumiant, Omvoh, and Taltz. Its neuroscience products include Emgality and Kisunla. The Company is also engaged in radiopharmaceutical discovery, development, and manufacturing efforts, and clinical and pre-clinical radioligand therapies in development for the treatment of cancer. It is also developing an oral small molecule inhibitor of a4b7 integrin for inflammatory bowel disease (IBD). It is evaluating its novel gene therapy candidate, ixoberogene soroparvovec.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
